Alzheimer Disease & Dementia

Discover how blarcamesine, a novel therapy for Alzheimer disease, shows promise in preventing cognitive decline and enhancing patient quality of life.

Susan Noonan, MD, discusses emerging research on the potential role of lithium deficiency in Alzheimer disease.

The FDA has approved the Leqembi subcutaneous autoinjector for at-home Alzheimer disease treatment.

Leqembi for the treatment of Alzheimer disease has been launched in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025—the first launches in the EU.

New research highlights lithium's crucial role in brain health, revealing its potential to combat Alzheimer disease and enhance mental wellness.

Anavex Life Sciences reveals significant cognitive and functional improvements in early Alzheimer disease patients using blarcamesine, highlighting its potential as a long-term treatment.

Acumen Pharmaceuticals reveals a breakthrough blood assay that enhances Alzheimer’s trial efficiency and highlights sabirnetug's selectivity for toxic amyloid beta oligomers.

Cognition Therapeutics reveals promising phase 2 results for zervimesine in treating dementia with Lewy bodies and Alzheimer disease at AAIC 2025.

Roche unveils promising Alzheimer disease treatments and diagnostic tools, including trontinemab and the Elecsys pTau217 blood test, at the AAIC conference.

Gerald Maguire, MD, shares insights on agitation in Alzheimer disease at the Southern California Psychiatry Conference.

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

Explore effective strategies for dementia risk reduction and understand the importance of early cognitive assessments in aging adults.

Check out the pipeline updates from April!

In this CME article, explore the complexities of Parkinson disease, focusing on neuropsychiatric symptoms, their prevalence, and effective treatment strategies for improved patient care.

Does trontinemab represent the next generation of anti-amyloid monoclonal antibodies thanks to Brainshuttle technology? New research looks encouraging.

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Check out the pipeline updates from January!

Here's why you should be paying attention to this new, upcoming Alzheimer disease treatment...

The lates update in lecanemab’s journey: the FDA has accepted the BLA for lecanemab-irmb subcutaneous autoinjector for weekly maintenance dosing.

The FDA grants Breakthrough Device Designation to Spear Bio’s pTau 217 blood test for Alzheimer disease.

The FDA has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody being investigated for the treatment of patients with early Alzheimer disease.

Do lifestyle interventions really work in Alzheimer disease and what are the underlying mechanisms? Learn more in this ACNP 2024 Annual Meeting session!

In this CME article, learn more about the efficacy and tolerability of brexpiprazole for the treatment of agitation among individuals with Alzheimer disease dementia.